Status:
TERMINATED
Effectivity of Postpartum Dexamethasone for Women With Class I HELLP Syndrome
Lead Sponsor:
Instituto Materno Infantil Prof. Fernando Figueira
Conditions:
HELLP Syndrome
Eligibility:
FEMALE
13-49 years
Phase:
PHASE4
Brief Summary
Corticotherapy accelerates maternal postpartum recovery in women with class I HELLP syndrome. The benefit of faster and better recovery would be observed in fewer complications, less utilization of bl...
Detailed Description
Patients with Class I HELLP Syndrome will be recruited for use os dexamethasone or placebo in the puerperium. Effects such as clinical course (blood pressure and diureses), laboratorial behaviour and ...
Eligibility Criteria
Inclusion
- Postpartum women with Class I HELLP syndrome
Exclusion
- Chronic users of corticosteroids
- Patients with chronic conditions affecting the laboratory parameters involved in the HELLP syndrome
- Women who had received antenatal corticosteroids to treat HELLP syndrome were excluded
Key Trial Info
Start Date :
July 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2019
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00711841
Start Date
July 1 2011
End Date
June 1 2019
Last Update
June 6 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto Materno Infantil Prof. Fernando Figueira
Recife, Pernambuco, Brazil, 50.070-550